Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Pact Pursues Hearing Loss Drugs

by Michael McCoy
October 15, 2012 | A version of this story appeared in Volume 90, Issue 42

[+]Enlarge
Credit: iStock
Roche says sensorineural hearing loss has no approved pharmaceutical therapies.
Stock photo of a woman receiving an ear exam.
Credit: iStock
Roche says sensorineural hearing loss has no approved pharmaceutical therapies.

Roche has joined with Inception Sciences and the private equity firm Versant Ventures to create a drug discovery incubator, Inception 3, that will seek treatments for sensorineural hearing loss. The collaboration will pursue drugs that target inner ear hair cell protection and regeneration in the cochlea. It will draw on technology from Stanford University.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.